新冠肺炎康复者血浆成“救命稻草”？治疗11名危重病患效果显著，但风险不可忽视。
Plasma "life-saving straw" in patients recovering from Newcomb Pneumonia has significant effect on 11 critically ill patients, but the risk should not be ignored.
都保杰。
Du Baojie.
DeepTech深科技                      。
Deep Technology DeepTech.
DeepTech深科技。
Deep Technology DeepTech.
DeepTech是一家关注新兴科技产业化的全链条内容、服务、数据和投融资平台，致力于构建一个全球科技创新合作网络。
DeepTech is a whole chain of content, services, data, and investment and financing platforms that focus on the industrialization of emerging technologies, and is committed to building a global science, technology, and innovation collaborative network.
。
.
2 月 13 日晚间，国药中国生物宣布了一项重要进展，在新冠肺炎康复者血浆中已检测出高效价病毒中和抗体，实验证明，能够有效杀死新冠病毒，“我们用康复者特异血浆临床治疗 11 例危重病人，治疗效果显著。
On the night of Feb. 13, Chinese Medicine announced an important advance in the detection of highly effective viral neutralization antibodies in plasma of patients recovering from Newcomial Pneumonia, which proved effective in killing the new crown virus. "We used specific plasma from convalescent patients to treat 11 critically ill patients.
” 中国生物官方宣称。
"Chinese biological authorities claim.
国家卫健委专家组成员卢洪洲对此表示，上海已准备开展血浆疗法，已有一例患者准备使用恢复期患者的血浆，血浆疗法已经非常成熟，在针对新冠病毒还没有明确特效药的情况下，血浆疗法显得尤为有价值。
Lu Hongzhou, a member of the national health committee, said the city was ready for plasma therapy, which was especially valuable in the absence of specific drugs for the new crown virus, as one patient was ready to use plasma from convalescent patients.
新冠特免血浆制品是由康复者捐献的含高效价新冠病毒特异性抗体的血浆，经过病毒灭活处理，并对抗新冠病毒中和抗体、多重病原微生物检测后制备而成。
The new crown plasma-free product is the plasma donated by the convalescent patients containing HPCV-specific antibodies, inactivated by virus and prepared after the neutralization of the new crown virus and the detection of multiple pathogenic microorganisms.
钟南山曾预测新冠肺炎疫情在 2 月中下旬可能到达高峰，截至 2 月 13 日 24 时，国家卫健委通报我国累计报告确诊病例 63851 例（湖北省核减 1043 例），累计治愈出院病例 6723 例（湖北省核减 269 例），累计死亡病例 1380 例（湖北省因重复统计，核减 108 例）。
As of 2400 hours on February 13, the National Health Commission had reported a cumulative total of 63,851 confirmed cases (1,043 in Hubei Province), 6,723 cases of discharge (269 cases in Hubei Province) and 1,380 cases of death (108 cases in Hubei Province).
疫情形势仍然严峻。
The situation remains critical.
在缺乏疫苗和特效治疗药物的前提下，血浆疗法能提高重症病例的临床救治效果、降低死亡率，这无疑是一个重磅好消息。
In the absence of vaccines and special-effects drugs, plasma therapy can improve the clinical treatment of severe cases and reduce mortality, which is undoubtedly a heavy pound of good news.
但事物总有两面性，新冠病毒特免血浆制品和特免球蛋白的制备能为整个疫情带来多大转机呢？图｜抗疫期间一名爱心人士在医院献血（来源：合肥晚报）专家倡议康复者献血据悉，中国生物目前已加快开展新冠病毒特免血浆制品和特免球蛋白的制备，并在中国生物武汉生物制品研究所、国药集团武汉血液制品有限公司、武汉市江夏区第一人民医院、武汉血液中心、中科院武汉病毒研究所、中国食品药品检定研究院的紧密合作下，投入临床救治重症患者。
But there are always two sides to things.How much difference can the preparation of new crown virus free plasma products and immunoglobulin bring about to the whole epidemic? A caring person donated blood to the hospital during the disaster and is now working closely with Wuhan Biological and Biological Research Institute, Wuhan Jiangxia District First People's Hospital, Wuhan Blood Center, Wuhan Chinese Academy of Sciences Wuhan Virus Research Institute, China Food and Drug Administration.
根据国家卫生健康委员会下发的《关于印发新型冠状病毒感染的肺炎诊疗方案（试行第五版）的通知》，明确提出可对重型、危重型病例的治疗可采用恢复期血浆治疗。
According to the Notification of the National Board of Health on the Issuance of Pneumonia Diagnosis and Treatment of New Coronavirus Infections (Trial Version 5), it is clearly stated that convalescent plasma can be used for the treatment of severe and serious cases.
从 1 月 20 日开始，中国生物经过筹备组建了相关团队，调集了相关装备设备及原材料，在武汉地区实施了新冠肺炎康复者血浆采集。
Since January 20, Chinese biology has been preparing to set up a relevant team, mobilize relevant equipment and raw materials, and carry out plasma collection of patients recovering from New Crown Pneumonia in Wuhan.
2 月 8 日，首期在江夏区第一人民医院开展了 3 名危重患者的新冠特免血浆治疗，目前连同后续医院治疗的危重病人超过了 10 人。
On 8 February, the first round of new plasma-free treatment for three critically ill patients was conducted at the First People's Hospital in Jiangxia District, and more than 10 critically ill patients are now being treated together with follow-up hospitals.
临床反映，患者接受治疗 12 至 24 小时后，实验室检测主要炎症指标明显下降，淋巴细胞比例上升，血氧饱和度、病毒载量等重点指标、临床体征和症状明显好转。
After 12 to 24 hours of treatment, the main inflammatory markers were significantly decreased, lymphocyte ratio increased, blood oxygen saturation, viral load, clinical signs and symptoms were significantly improved.
专家表示，从临床病理发生过程看，大部分新冠肺炎患者经过治疗康复后，身体内会产生针对新冠病毒的特异性抗体，可杀灭和清除病毒。
Experts said that the clinical pathology process, most patients with new crown pneumonia after treatment and rehabilitation, the body will produce a new crown virus-specific antibody, can kill and remove the virus.
中国生物研发相关负责人表示，新冠病毒特免血浆的采集、制备和系列检测过程，具有良好的安全性，制备工艺成熟，所需时间短。
China's biological research and development, said the new cap virus special plasma collection, preparation and series of testing process, with good security, mature preparation process, the time required.
目前在缺乏疫苗和特效治疗药物的前提下，采用这种特免血浆制品治疗新冠病毒感染是最为有效的方法，可大幅降低危重患者病死率。
At present, in the absence of vaccines and special-effects drugs, this special plasma treatment is the most effective way to significantly reduce the fatality rate of critically ill patients.
在 2 月 13 日晚召开的湖北省第 23 场新冠肺炎疫情防控工作新闻发布会上，武汉金银潭医院院长张定宇在回答如何提高救治、降低死亡率等记者提问时也提到，重症、危重症患者数量不断增加，导致了死亡病例的绝对数略有升高，死亡病例主要还是以老人和有基础疾病的一些病人为主。
In response to a question from reporters on how to improve treatment and reduce mortality, Zhang Dingyu, director of Wuhan Gold and Silver Pool Hospital, said at a press conference on the night of Feb. 13 that the absolute number of fatal cases was rising slightly, mainly among the elderly and some patients with basic diseases.
武汉金银潭医院是新冠肺炎重症收治的定点医院，目前医院在开展康复病人的恢复期血浆的输注，显示出了初步的效果。
The gold and silver pool hospital in Wuhan is a designated hospital for severe treatment of Newwalled Pneumonia. At present, the infusion of plasma in convalescent patients shows initial results.
张定宇倡议，“因为康复的患者体内有大量的综合抗体对抗病毒，在此也恳请康复后的一些患者，积极来到我们医院伸出你的胳膊，捐献出宝贵的血浆，我们共同来拯救还在与病魔做斗争的这些病人。
Zhang Dingyu Initiative, "because the convalescent patients have a large number of antibodies on antiviral, here also implore some patients after rehabilitation, actively come to our hospital to extend your arms, donate valuable plasma, we together to save these patients are still struggling with the disease.
”中国生物发布的新冠肺炎康复者血浆捐献倡议书中提到一些细节。
The Chinese biology released a plasma donation initiative for patients recovering from New Crown Pneumonia, which includes some details.
例如，康复者捐献血浆须具备一定的条件，年龄范围在 18-60 周岁，确诊感染过新型冠状病毒，出院后目前身体状况较好，没有其他不适；需在献血点经过登记、健康征询、体格检查，符合要求进行血浆采集（约 20-30 分钟）；前一天尽量清淡饮食，不能空腹献血浆，女性月经期内不能献血浆；康复者捐献血浆后注意按压穿刺点 20-30 分钟，注意针眼处清洁卫生，不可用水擦洗；献血后要保持健康的生活方式，间隔 14 天后可再次捐献血浆。
For example, a convalescent person who donates plasma must meet certain conditions. He is aged between 18 and 60, has been diagnosed with a new coronavirus and is now in good condition (about 20-30 minutes).
DeepTech 致电献血处人士了解到，依据《中华人民共和国献血法》及《献血者健康检查要求》相关规定，全血献血者每次可献全血 400ml，或者 300ml，或者 200ml。
DeepTech called blood donors to learn that, according to the Law of the People's Republic of China on Blood Donation and the Requirements for Medical Examination of Blood Donors, all blood donors can offer 400 ml, or 300 ml, or 200 ml of blood at a time.
武汉地区的新冠肺炎康复者血浆采集工作优先考虑本地就近能来的康复者，截至发稿前，咨询电话已有很多，工作人员需要进行初步的判断筛选，现在还没有来到医院献过血的人，但相信很快会有爱心献血者过来进行支援。
In Wuhan, priority is given to the blood collection of newly recovered patients with new crown pneumonia. By the time of writing, the number of consultation calls has reached a high level, staff members need preliminary screening, and no one has come to the hospital to donate blood, but it is believed that a loving donor will come soon to assist them.
图｜装有血液和提取出血浆的试管（来源：网络）这并不是第一次利用康复者的血液来对抗传染病疫情，救治危重患者，这并不是第一次。
This is not the first time that the blood of a recovering patient has been used to fight an epidemic and treat a critically ill patient.
2003 年 SARS 流行期间, 北京 、香港等地曾使用 SARS 患者康复期血清成功救治多例危重 SARS 病人, 证实恢复期病人的抗体有治疗作用，而且康复者一次捐献血浆 200 至 400 毫升对身体健康不会有太大影响，献血者需要的化验项目一般包括 ALT 、HBSAG 、抗 - HCV 、抗 HIV 、梅毒 、血色素 、血型、血浆总蛋白等 。
During the SARS epidemic in 2003, patients with severe SARS were successfully treated with serum from Beijing and Hong Kong during the convalescent period. It was confirmed that antibodies of convalescent patients had therapeutic effects and that the convalescent patients' donation of 200 to 400 ml of plasma had little effect on health.
不过临床使用 SARS 患者康复期血清时有一个关键问题, 当时有业内专家认为，虽然进行了血型配伍试验及病原微生物如甲肝、乙肝、丙肝、艾滋、梅毒螺旋体等的检测, 但病人恢复期血浆中仍然存在其他未知病原微生物, 甚至存留 SARS 冠状病毒等感染的潜在危险, 因此存在血源传播相关疾病的可能。
However, there was a key issue in the clinical use of serum from patients with SARS. Industry experts believed that although blood compatibility tests and testing of pathogenic microorganisms such as hepatitis A, hepatitis B, hepatitis C, AIDS and Treponema pallidum, other unknown pathogenic microorganisms still exist in the patient's convalescent plasma, and even the potential risk of infection such as SARS coronavirus.
解放军 302 医院姜素椿教授曾表示，利用非典康复者产生的血清抗体，帮助杀死危重非典患者体内的 SARS 病毒，只是在既无特效药又无疫苗的特殊时期的救命措施。
Professor Jiang Su-chun at PLA 302 Hospital has said that the use of serum antibodies produced by SARS patients helped kill SARS virus in critically ill SARS patients, only as a life-saving measure during specific periods when there were neither specific nor vaccines.
应该看到，我国有完善的血液管理体系、血液管理法规，通过我国施行的 7 项指标的检验，基本能够保证血液安全。
It should be noted that China has a sound blood management system, blood management regulations, through the implementation of seven indicators of the test, basically can ensure blood safety.
另外，世界卫生组织关于中东呼吸综合征冠状病毒（MERS）的一份总结资料中提到，在临床前模型中，具备中和活性的多种单克隆和多克隆抗体制剂可以抑制 MERS 病毒。
In addition, a WHO summary of the coronavirus associated with the Middle East respiratory syndrome (MERS) notes that in pre-clinical models, multiple monoclonal and polyclonal antibody agents with neutralizing activity can inhibit the MERS virus.
不过，迄今并没有使用这些制剂或恢复期血浆治疗 MERS 病毒感染患者的确切数据，只是对用恢复期血浆治疗严重 MERS 病毒患者进行的系统审查和探索性分析显示死亡率下降，因此恢复期血浆被认为可能用于治疗。
However, to date, no precise data on the use of these agents or convalescent plasma for the treatment of MERS virus patients have been used, except for the systematic review and exploratory analysis of convalescent plasma treatment of severe MERS virus patients, which has shown a decrease in mortality, and therefore convalescent plasma is considered a possible therapeutic use.
但是，恢复期血浆，特别是带有确定水平的中东呼吸综合征冠状病毒中和抗体的恢复期血浆，仍然极为有限。
However, convalescent plasma, especially convalescent plasma with a definitive level of coronavirus neutralization of the Middle East respiratory syndrome, remains extremely limited.
上面提到的血浆和血清，有什么区别？简单来说，血浆（Plasma）是将血液加入抗凝剂后离心得到的上清液，抗凝剂的存在阻断了凝血反应，使凝血过程受阻，纤维蛋白原还存在于血浆中。
What's the difference between plasma and serum? Simply put, plasma (Plasma) is a centrifugal supernatant obtained by adding blood to an anticoagulant, the presence of which blocks the coagulation response and blocks the coagulation process, which is still present in plasma.
因此，血浆的化学成分中，水分占 90%～92％，其他 10% 以溶质血浆蛋白为主，并含有盐、营养素、酶类、激素类、胆固醇等各种元素。
Therefore, 90% ~ 92% of the plasma chemical composition, the other 10% to solute plasma protein, and contains salt, nutrients, enzymes, hormones, cholesterol and other elements.
血清（Serum）是离体的血液发生凝血反应后形成的上层淡黄色透明液体。
Serum (Serum) is a clear, yellowish liquid formed after coagulation in isolated blood.
凝血的主要反应是纤维蛋白原转化为纤维蛋白，所以血清中不再含有纤维蛋白原，这一点是与血浆最大的区别。
The main reaction of coagulation is the conversion of fibrinogen into fibrinogen, so the serum no longer contains fibrinogen, which is the biggest difference from plasma.
但大量未参加凝血反应的物质则与血浆基本相同。
However, a large number of substances not involved in clotting were essentially the same as plasma.
图｜从血液中提取血清和血浆的区别（来源：维基生物）实际上，很多病毒感染引起的疾病并没有针对性的特效药物来治疗和预防，这些疾病大多是自限性，也就是机体通过抗体反应等免疫反应将病毒清除。
The difference between serum and plasma extracted from the bloodstream (source: Wikipedia) In fact, many diseases caused by viral infections are not treated and prevented by specific drugs, most of which are self-limited, meaning that the body clears the virus through immune responses such as antibody reactions.
通过输入康复者血浆或者血清，危重患者就能获得外来抗体的援助，从而得到被动保护。
By injecting blood plasma or serum from a recovering patient, a critically ill patient can receive assistance from a foreign antibody, thereby receiving passive protection.
其实，人类早在 100 多年前，就开始使用血清疗法来对抗细菌引起的传染病了。
In fact, humans began to use serum therapy to fight bacterial infections more than 100 years ago.
1891 年 12 月 10 日，在柏林大学附属诊疗所的儿科病房，德国医生埃米尔 · 贝林给一个濒死的白喉病患儿注射了一种血清，这种血清里含有白喉抗毒素。
On 10 December 1891, in the paediatric ward of the University of Berlin's dispensary, the German doctor Emil Behring injected a child with diphtheria near death with a serum containing diphtheria antitoxin.
第二天，患儿的病情明显好转。
The next day, the child's condition improved markedly.
这是医学史上的一个重要里程碑，开启了人类防治传染病一条新路。
This is an important milestone in the history of medicine, opening a new way for mankind to control infectious diseases.
贝林因在理论上和临床上，成功验证血清疗法防治白喉，破伤风的有效性，从而得到全世界医学界的肯定，于 1901 年获第一届诺贝尔生理学或医学奖。
Belin was awarded the first Nobel Prize in Physiology or Medicine in 1901 for his success in proving the effectiveness of serum therapy in the prevention and treatment of diphtheria and tetanus, both theoretically and clinically.
不应忽视的风险从病毒免疫者血液里提取出病毒抗体用于患者治疗，最终克服疫情的故事情节我们经常在科幻电影中看到，然而，这种做法能否在当下新冠疫情中大范围推广？从技术上看，提取新冠病毒特免血浆没有任何难题。
The risk that should not be ignored is that viral antibodies are extracted from the blood of viral immunizers for patient treatment, and the story of eventually overcoming the epidemic is often seen in science fiction films.
关键因素在于抗体的浓度，首先要在病人康复后，确定他已经不携带病毒，如通过数次核酸检测都已呈阴性；其次就是测抗体，要看康复者体内的病毒抗体到底有多少，因为要有治疗作用，抗体必须达到一定的数量和浓度；最后是提取血浆，得到抗病毒成分。
The key factor is the concentration of the antibody. After the patient recovers, it is determined that he is no longer carrying the virus, e.g. he has been tested negative for several nucleic acid tests. Secondly, antibodies are measured by the amount and concentration of viral antibodies in the recovered person.
而从血液中进一步提取出有效抗体的实际操作是困难的。
The actual operation of further extraction of effective antibodies from the blood is difficult.
有研究显示，康复病人的体内会产生抗原特异性的 B 细胞，通过筛选捕获这些有抗原特异性 B 细胞，再进行序列的扩增和分析，便可以得到有效的全人源单克隆抗体序列，随后便可以在体外制备抗体了。
Studies have shown that in convalescent patients, antigen-specific B cells are produced in vivo, and effective whole-person monoclonal antibody sequences can be obtained by screening and trapping these antigen-specific B cells for sequencing and analysis, and antibodies can then be prepared in vitro.
而从血液中进一步提取出有效抗体的实际操作是困难的。
The actual operation of further extraction of effective antibodies from the blood is difficult.
有研究显示，康复病人的体内会产生抗原特异性的B细胞，通过筛选捕获这些有抗原特异性B细胞，再进行序列的扩增和分析，便可以得到有效的全人源单克隆抗体序列制备抗体了。
In convalescent patients, antigen-specific B cells are produced in vivo, and effective whole-person monoclonal antibody sequences can be prepared by screening and trapping these antigen-specific B cells and amplifying and analyzing the sequence.
然而抗原特异性B细胞在外周血液中含量十分稀少，在一项研究中，研究者在外周血中分离到的抗原特异性B细胞比例仅为19/500000。
However, antigen-specific B cells were scarce in peripheral blood, and in one study the researchers isolated only 19 / 500,000 antigen-specific B cells from peripheral blood.
此外，病毒蛋白质包含多种异己的蛋白质，对于任何一种异己的蛋白质，人类机体都有可能产生专门针对它的抗体，在新型冠状病毒感染者体内可以产生多种不同的针对病毒的多类抗体，但很多抗体缺乏抗病毒作用，只有针对病毒表面蛋白质的抗体才可能产生抗病毒的效果。
In addition, viral proteins contain a variety of heterologous proteins, against which the human body may produce antibodies that are specific to it. Many antibodies produce a variety of antibodies against the virus in people infected with the new coronary virus. However, many antibodies lack antiviral action and only antibodies against proteins on the virus's surface can have an antiviral effect.
不容忽视的是，这种利用康复者血浆的治疗方法也隐含着一定的风险和局限性。
It cannot be ignored that this method of plasma treatment of rehabilitated persons also implies certain risks and limitations.
SARS 和 MERS 的实际经验表明，有两个重要的前置条件：一是对血清或特免血浆治疗安全性、复杂性和风险性把控，当前新冠肺炎第一批康复患者其实也才康复不久，我们对于恢复期血液组分的认知和功能其实还没有研究透彻，因此将处理后的血浆直接注射到其他人的体内或许仍存在风险；二是带有合规水平病毒抗体的血浆本身就十分有限，还需要进行血型配对，无法应对数以万计的确诊患者数量，临床可能只应用于少数危重患者试验性救治更切实一点，这也是为什么当前一直采取隔离治疗措施，并在分离出病毒毒株后把加急有效药临床试验或推进疫苗研发作为重点，大多数患者其实用不上血清抗体或特免血浆治疗。
The actual experience of SARS and MERS shows that there are two important prerequisites: first, control of the safety, complexity and risks of serum or plasma-free treatment, currently the first convalescent patients have only recently recovered. Second, our knowledge and function of the convalescent plasma is limited.
另外，有临床医生表示，未经提纯的抗体连同血液输入患者体内，对患者来说，就是强大的异体抗原，生物体会对进入体内的异原物质进行强大的排斥反应。
In addition, some clinicians say that unpurified antibodies, together with blood transfusions, are powerful heterologous antigens for patients, and organisms react strongly to the repulsion of foreign substances that enter the body.
也就是说，直接输入血液抗体的结果，很有可能引起接受者的急性移植排斥反应，患者体内短时间内出现大量免疫炎症因子和针对外来物质的抗体，血液中血细胞发生凝集反应，身体多器官功能衰竭而威胁生命安全。
In other words, the direct input of blood antibodies is likely to trigger an acute transplant rejection by the recipient, a short period of time in the body of a large number of immune inflammatory factors and anti-foreign substances, blood cells in the blood coagulation reaction, the body multi-organ function failure and life-threatening.
因此，利用康复者特异血浆用于临床，只是目前既无特效药又无疫苗的特殊时期的救命措施，只是针对少数危重患者的特殊治疗方法，不宜大规模应用。
Therefore, the specific plasma of convalescent patients for clinical use, only no specific period of life-saving measures, neither specific drugs nor vaccines, only special treatment for a few critically ill patients, not large-scale application.
-End-参考：https://apps.who.int/iris/bitstream/handle/10665/178529/WHO_MERS_Clinical_15.1_chi.pdf?sequence=11&isAllowed=yhttps://wxn.qq.com/cmsid/20200131A05TJZ00http://url.cn/5HjR9t4。
- End-reference: https: / / apps.who.int / iris / bitstream / hand / 10665 / 178529 / WHO _ MERS _ Clinton _ 15.1 _ chi.pdf? search = 11 & ampp; isAlled = yhttps: / / wxn.qq.com / cmsid / 20200131A05TJZ00http: / / url.cn / 5HjR9t4
发送到看一看 。
Send it to see.
新冠肺炎康复者血浆成“救命稻草”？治疗11名危重病患效果显著，但风险不可忽视。
Plasma "life-saving straw" in patients recovering from Newcomb Pneumonia has significant effect on 11 critically ill patients, but the risk should not be ignored.
长按识别前往小程序。
Long press identify to go to the applet.
var _ori_article_type = "健康医疗";。
var _ ori _ article _ type = & quot; Health & quot;;
var nickname = "DeepTech深科技";。
var nickname = & quot; DeepTech & quot;;
var msg_title = "新冠肺炎康复者血浆成“救命稻草”？治疗11名危重病患效果显著，但风险不可忽视";。
Var msg _ title = & quot; & # 160; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45;
var msg_desc = "2 月 13 日晚间，国药中国生物宣布了一项重要进展，在新冠肺炎康复者血浆中已检测出高效价病毒中和抗体，实";。
var msg _ desc = & quot; & quot; & quot; & quot; & quot; & quot; & quot; & quot; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & quot; & quot; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & quot; & quot; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & quot; & quot; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & # 45; & quot;
var title ="DeepTech深科技";。
var title = & quot; DeepTech & quot;;
